H. Lundbeck A/S H. Lundbeck A/S

H. Lundbeck A/S

HLUN-A

株式のランク #2966
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
株価
$7.26
時価総額
$6.08B
変化(1日)
2.66%
変化(1年)
31.10%
国
DK
取引 H. Lundbeck A/S (HLUN-A)

カテゴリー

Healthcare
H. Lundbeck A/S(HLUN-A)の株価履歴
終値の最高値: $7.00 (2026-10-01)

終値の最安値: $4.77 (2022-06-01)
H. Lundbeck A/S の株価履歴(2022 ~ 2026)
年間株価パフォーマンス
年 パフォーマンス
2026 (TTM) 6.59%
2025 13.54%
2024 13.71%
2023 20.95%
2022 0.00%
類似企業または競合の株価
企業 株価 変化率 1年% 国
$63.75 73.05%
US
$45.98 36.92%
SE
$172.16 24.48%
FR
$59.52 -0.48%
IT
$109.15 48.20%
US